Department of Urologic Oncology, M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Urol Oncol. 2012 May-Jun;30(3):266-72. doi: 10.1016/j.urolonc.2010.04.002. Epub 2010 Sep 25.
Patients diagnosed with upper tract urothelial carcinoma (UTUC) sometimes experience a delay from diagnosis to extirpative surgery (nephroureterectomy or ureterectomy) as a result of attempted endoscopic management and/or neoadjuvant chemotherapy. The purpose of this analysis is to examine the impact of such delay on survival outcomes.
An IRB-approved retrospective review identified consecutive patients undergoing extirpative surgery for UTUC treated at a single institution between 1990 and 2007. 240 patients with non-metastatic disease represented both primarily-presenting and referred patients. Patients in the "early" surgery group underwent extirpative surgery <3 months after diagnosis and patients in the "delayed" surgery group underwent surgery ≥ 3 months after diagnosis. Timing to surgery was at the discretion of individual patient-surgeon decision-making. Analyses and measurements were univariate and multivariate models correlating death from disease with clinico-pathologic parameters, recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) in the "early" and "delayed" surgery groups.
186 patients underwent early surgery and 54 patients underwent delayed surgery. Median follow-up for all patients was 29 months. The 5-year CSS were 72% and 71% for the early versus late groups, respectively (P = 0.39) and corresponding 5-year OS rates were 60% and 69%, respectively (P = 0.69). Delay in surgery was not associated with a worse outcome, even following adjustment for potential confounders. The most common factor contributing to delayed surgery in our cohort was administration of neoadjuvant chemotherapy (50%), which did not impact survival. Limitations included a median follow-up of 19 months in the neoadjuvant group; and the requirement to analytically group pathologic high-stage and low-stage disease, which reflects challenges inherent to current clinical staging.
Our results show no difference in survival between patients undergoing early versus delayed extirpative surgery for UTUC, suggesting the feasibility of delayed surgery in appropriately selected patients. Only prospective validation of delayed surgery can guarantee its safety.
由于尝试内镜治疗和/或新辅助化疗,部分上尿路上皮癌(UTUC)患者在诊断后至根治性手术(肾输尿管切除术或输尿管切除术)之间会出现时间延迟。本分析旨在研究这种延迟对生存结果的影响。
经机构审查委员会批准的回顾性研究,分析了 1990 年至 2007 年间在单一机构接受根治性手术治疗的非转移性 UTUC 连续患者。240 例患者为初诊和转诊患者。“早期”手术组的患者在诊断后<3 个月接受根治性手术,“延迟”手术组的患者在诊断后≥3 个月接受手术。手术时间由患者与外科医生的个体决策决定。分析和测量采用单变量和多变量模型,将疾病死亡与临床病理参数、无复发生存(RFS)、癌症特异性生存(CSS)和“早期”与“延迟”手术组的总体生存(OS)相关联。
186 例患者接受了早期手术,54 例患者接受了延迟手术。所有患者的中位随访时间为 29 个月。早期组和晚期组的 5 年 CSS 分别为 72%和 71%(P=0.39),相应的 5 年 OS 率分别为 60%和 69%(P=0.69)。即使在调整了潜在混杂因素后,手术延迟与较差的预后无关。本队列中手术延迟的最常见因素是新辅助化疗(50%)的应用,但不影响生存。研究存在一定局限性,包括新辅助组中位随访时间为 19 个月;以及需要对病理高分期和低分期疾病进行分析分组,这反映了当前临床分期所固有的挑战。
我们的研究结果表明,UTUC 患者接受早期与延迟根治性手术的生存结果无差异,提示在适当选择的患者中延迟手术是可行的。只有前瞻性验证延迟手术才能保证其安全性。